Oct 2, 2019 — 5 min read
New York, NY, October 2, 2019 -- CB Insights today named Lunit to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital health companies in the world. CB Insights CEO Anand Sanwal revealed the final Digital Health 150 during Future of Health, a gathering of top executives across some of the largest healthcare institutions, startups, and investment firms.
“From pharmaceuticals to patient care, technology is rapidly changing healthcare, and The Digital Health 150 showcases the 150 best startups spearheading innovation and change in the sector,” said CB Insights CEO Anand Sanwal. “It's a privilege to use CB Insights' data to identify and shine a light on these companies, and we look forward to tracking their success in 2019 and beyond."
The Digital Health 150 companies span the globe, from Canada, China, Germany, Israel, the United States, and the United Kingdom, and are supported by more than 850 investors.
“It is an honor to be recognized by CB Insights as leading digital health company in Imaging Diagnostics,” said Lunit CEO Brandon Suh. "Lunit has also been selected by CB Insights in 2017 'AI 100' list, and the continued recognition is truly empowering for us in the journey of paving the future of health."
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.
Lunit develops AI softwares that can solve some of the most important problems today in cancer diagnosis and treatment. Lunit's AI solution for imaging tests such as mammography and chest x-ray has been developed with deep learning technology and is known to accurately detect the abnormalities---providing location and probability of the lesion existence---in breast and lung images, including cancer. A study published in Radiology shows that, when accompanied with Lunit's algorithm, the physician's diagnostic performance can increase by upto 20%.
In 2018, these emerging private companies cumulatively raised $5.7B across 117 deals. They're on track to surpass these numbers in 2019, with $3B raised across 73 deals as of Q2'19.
A total of 17 companies have reached a unicorn valuation of $1B or more. GRAIL, Oscar Health, and We Doctor round out the top three most funded companies on the list.
116 of the Digital Health 150 are headquartered in the United States. Those based outside the United States include 17 from Asia, 16 from Europe, and 1 from Canada.
Over 850 unique investors have funded the Digital Health 150, with F-Prime Capital, New Enterprise Associates, and Google Ventures taking the top three spots as the most active investors.
23andMe, 98point6, AbleTo, Accolade, Ada Health, Aetion, AiCure, Aidoc Medical, Akili Interactive Labs, Alan, American Well, Arterys, Athelas, Atomwise, Ava Science, Babylon Health, Beam Dental, Benchling, Bend Financial, Biofourmis, Bright Health, Buoy Health, Butterfly Network, Calm, Cara Care, CarePredict, Carrot Fertility, Cedar, Ciitizen, Cityblock Health, ClearCare, ClearDATA, Click Therapeutics, Collective Health, Color , Cricket Health, Cue Health, CureApp, Deep Lens, Devoted Health, DispatchHealth, DocPlanner, Doctolib, Doctor On Demand, Dreem, Emulate, Evidation Health, eXo Imaging, Freenome, Galileo Health, Gauss Surgical, Genome Medical, Glooko, GNS Healthcare, GoodRx, GRAIL, Grand Rounds, Halodoc, Headspace, HealthVerity, Healthy.io, HeartFlow, higi, Hims, Human API, icometrix, IDx, Insitro, Iora Health, Jvion, K Health, Kaia Health, KenSci, Kindbody, Kry, Kyruus, Lark Health, LEAGUE, Letsgetchecked, Lifetrack Medical Systems, LinkDoc Technology, Luna DNA, Lunit, Lyra Health, Maven Clinic, MDClone, MDLIVE, Medbanks Network Technology, Modern Health, MORE Health, Nebula Genomics, Neurotrack Technologies, Niramai, Nomad Health, Noom, Notable, Nurx, Olive, Omada Health, Oncology Analytics, One Medical, Oscar Health, Oura Health, OWKIN, PAIGE.AI, Parsley Health, PathAI, PatientPing, Pear Therapeutics, Pill Club, Pivot, Proscia, Protenus, Proteus Digital Health, Quartet Health, RDMD, Recursion Pharmaceuticals, Redox, Ro, Solera, Solv Health, Sophia Genetics, Stride Health, Suki, SWORD Health, Syapse, SYNYI.AI, Talkspace, Teckro, Tempus, Tencent Trusted Doctors, TriNetX, TruePill, TytoCare, Unite Us, Verana Health, Vida Health, Vim, Vineti, Viome, Virta Health, Vivante Health, Viz.ai, VoxelCloud, We Doctor, Wei Mai, Welkin Health, Xiaolu Yiguan, Zava, Zebra Medical Vision
At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.
Lunit, abbreviated from “learning unit,” is an AI software company devoted to providing "AI-powered total cancer care," by developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge deep learning technology.
Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images. It has been named by CB Insights as one of “AI 100” startups transforming healthcare industry. Lunit's technology has been recognized at international competitions such as ImageNet (5th place, 2015), TUPAC 2016 (1st place), and Camelyon 2017 (1st place), surpassing top companies like Google, IBM, and Microsoft. Lunit is based in Seoul, South Korea.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021